



Pioneering science delivers vital medicines™



Amgen BC Quick Facts

Amgen believes in the transformative power of science to bring the benefits of biotechnology to more people than ever before. Amgen's Canadian research facility in Burnaby, British Columbia plays an important role in contributing to our 30-year legacy as a global leader in the identification, isolation, production and use of human proteins as therapeutic agents. The Amgen commercial team in BC works in partnership with the provincial government and other stakeholders to bring practical, cost-effective and long-term improvements to the healthcare system in British Columbia.

Today, Amgen scientists in Burnaby work on the cutting edge between the traditional disciplines of chemistry, cellular and molecular biology in an effort to discover and develop pioneering medical treatments. Our research leverages new scientific breakthroughs for patient care – from the laboratory to treatment – faster and safer than ever before, helping patients in their fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

Amgen BC's Innovative Technology

Amgen BC's research centre is a custom-built, state-of-the-art laboratory, incorporating novel, proprietary technologies to isolate, develop and produce potential medicines. This world-class biotechnology lab enables Amgen BC to produce superior research results that translate into better therapeutic treatments.

Key to Amgen BC's leadership in biotechnology is our focus on advancing Amgen's most promising, innovative, potential new therapeutics into clinical studies, while significantly expanding the organization's understanding of the underlying causes of diseases

Amgen BC's cutting-edge XenoMouse™ technology produces human antibodies that can be refined for therapeutic treatment. The complementary XenoMax™ process and proprietary SLAM technology accelerate our ability to identify the best potential research candidates and isolate individual cells for further study. These progressive research tactics mean Amgen BC identifies the most promising antibody candidates far earlier in the research and development timeline than before.

QUICK FACTS

Location: Burnaby, British Columbia

Staff:

Burnaby – Approx. 60
Commercial Field staff – 15

Key Functions:

- Research and Development
- Commercial Operations

Address/Phone

Amgen British Columbia Inc.
7990 Enterprise Street
Burnaby, British Columbia
Canada V5A 1V7
Phone: (604) 676-8300

HISTORY IN BC

- 1991 – Amgen Canada is established
- 1993 – ImmGenics Pharmaceuticals Inc. is founded in British Columbia
- 1999 – Abgenix licenses Amgen to use its XenoMouse™ technology
- 2000 – Abgenix acquires ImmGenics and SLAM technology developed by UBC's Biomedical Research Centre
- 2002 – Abgenix and Amgen enter co-development agreement for panitumumab
- 2003 – The current research and development facility in Burnaby is completed
- 2006 – Amgen acquires Abgenix Inc., including its Burnaby R&D group

PRIMARY THERAPEUTIC CATEGORIES

- Cancer
- Kidney Disease
- Bone Health
- Severe Inflammation
 - Rheumatoid arthritis
 - Psoriatic arthritis
 - Juvenile rheumatoid arthritis
 - Ankylosing spondylitis
 - Psoriasis

Educational Institutions

- University of British Columbia
- Simon Fraser University
- BC Institute of Technology
- University of Victoria
- University of Northern BC

Organizations

- LifeSciences BC
- Rx&D
- Post-Consumer Pharmaceutical Stewardship Association

ABOUT AMGEN

Amgen (NASDAQ: AMGN) discovers, develops and delivers innovative human therapeutics. Amgen's mission is to serve patients. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

Formed in 1991, Amgen Canada is based in Mississauga, Ontario. Today there are approximately 400 Amgen employees in Canada with approximately 65 based in British Columbia.

Headquartered in Southern California and with offices in 35 countries, Amgen has nearly 20,000 staff members worldwide. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.ca.

Commitment to British Columbia

Amgen believes that biologic medicines have the power to change the ways we can fight disease and promote health, and the exciting scientific research being conducted in British Columbia is leading the way. Amgen's leadership in biotherapeutic research is underscored by our corporate commitment to re-investing our sales revenue back into research in Canada. Our Burnaby facility represents a robust and ongoing investment in the BC life sciences industry.

Many of Amgen BC's proprietary research innovations were developed or invented in BC – a testament to the tremendous scientific talent pool that has been trained here and works in this province. We strive to attract the best and brightest minds from British Columbia's post-secondary and graduate science education programs. We also believe in investing in tomorrow's great scientists, providing nurturing opportunities for aspiring students to gain solid work experience through active participation in BC's co-operative education programs and other science education and mentoring programs.

Amgen BC is also involved in the community and is proud to contribute to a number of worthwhile causes in the province including sponsoring a number of internship positions for students from BC universities.

Amgen's Commitment to the Canadian Healthcare System

Amgen works in partnership with many of Canada's leading health care, academic, research, government and patient organizations to improve the health and well-being of patients dealing with serious illnesses. Our continued support of the biosciences research sector in BC and across the country contributes to the potential for new medicines or new uses for existing medicines.

Amgen Medicines Available in British Columbia

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic kidney disease. It is also prescribed for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.

Enbrel® (etanercept) is indicated for the treatment of moderately-to-severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and chronic moderate to severe plaque psoriasis.

Neulasta® (pegfilgrastim) or **NEUPOGEN®** (filgrastim) is indicated to reduce the incidence of infection (initially marked by a low white blood cell count and fever) in certain cancer patients who are receiving chemotherapy that could decrease their number of infection-fighting white blood cells. Neulasta® is a longer-acting form of NEUPOGEN® that requires only one injection per chemotherapy cycle.

Sensipar® (cinacalcet HCl) is an oral therapy prescribed to treat hyperparathyroidism caused by chronic kidney disease; it is approved for use in patients with chronic kidney disease receiving dialysis.

Vectibix® (panitumumab) is indicated as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Nplate® (romiplostim) is the first and only platelet producer approved in Canada for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral and hip fractures.